Genmab

GMAB · Nasdaq Copenhagen · DKK

kr 2,257.00−2.42%−kr 56.00

Close · October 2, 2026

At a glance

Revenue growth
+19.19%
2025 vs 2024
Net income growth
−15.00%
2025 vs 2024
Net margin
25.9%
2024: 36.3%

Financial data

Amounts in millions of USD; per-share values in USD; shares in millions.

ItemQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023Q3 2023
Total revenue1,1558961,0581,0229257151,027829779603706668
Cost of revenue84.065.081.058.057.042.053.040.828.027.018.711.2
Gross profit1,071831977964868673974788751576687657
Selling, general and administrative205166208148144126196129129125139122
Research and development459440526357364359431341361335289296
Operating income407225243459360188347317261116260239
EBIT407225243459360188347317261116260239
EBITDA423244253471376204353330271126265248
Interest expense11011244.03.09.05.08.82.73.04.03.11.3
Pre-tax income29574.055.0482423244554257307249149379
Income tax-8.021.024.081.087.049.0-24.067.810457.045.180.3
Net income30353.031.0401336195578189203192104298
Net income to common shareholders30353.031.0401336195578189203192104298
Basic EPS4.940.840.506.515.443.069.102.983.152.961.604.57
Diluted EPS4.910.830.506.465.423.059.002.963.132.941.584.53
Average shares (basic)61.363.161.661.661.863.763.563.564.464.965.365.3
Average shares (diluted)61.763.963.162.162.063.964.263.964.965.366.165.9